Next Article in Journal
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Next Article in Special Issue
TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy
Previous Article in Journal
Role of Phosphodiesterase in the Biology and Pathology of Diabetes
Previous Article in Special Issue
Pericyte-Endothelial Interactions in the Retinal Microvasculature
Review

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches

1
Department of Experimental Medicine, University Tor Vergata, Viale Oxford, 00133 Rome, Italy
2
Scientific Institute San Raffaele, University Vita Salute, 20132 Milan, Italy
3
Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
4
Department of Pharmacology, Medical School, Catholic University, 00198 Rome, Italy
5
University Eye Clinic Luigi Sacco Hospital, 20157 Milan, Italy
6
Molecular Partners AG—Wagistrasse, 14 8952 Zurich-Schlieren, Switzerland
7
Institute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Newark, NJ 07103, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(21), 8242; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21218242
Received: 5 October 2020 / Revised: 24 October 2020 / Accepted: 30 October 2020 / Published: 3 November 2020
Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatments cures the disease or reverses its course. Medical treatment of neovascular AMD experienced a significant advance due to the introduction of vascular endothelial growth factor inhibitors (anti-VEGF), which dramatically changed the prognosis of the disease. However, although anti-VEGF therapy has become the standard treatment for neovascular AMD, many patients do not respond adequately to this therapy or experience a slow loss of efficacy of anti-VEGF agents after repeated administration. Additionally, current treatment with intravitreal anti-VEGF agents is associated with a significant treatment burden for patients, caregivers, and physicians. New approaches have been proposed for treating neovascular AMD. Among them, designed ankyrin repeat proteins (DARPins) seem to be as effective as monthly ranibizumab, but with greater durability, which may enhance patient compliance with needed injections. View Full-Text
Keywords: age-related macular degeneration; neovascular AMD; neovascularization; vascular endothelial growth factor; anti-VEGF; Ang-2; DARPins age-related macular degeneration; neovascular AMD; neovascularization; vascular endothelial growth factor; anti-VEGF; Ang-2; DARPins
Show Figures

Figure 1

MDPI and ACS Style

Ricci, F.; Bandello, F.; Navarra, P.; Staurenghi, G.; Stumpp, M.; Zarbin, M. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int. J. Mol. Sci. 2020, 21, 8242. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21218242

AMA Style

Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences. 2020; 21(21):8242. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21218242

Chicago/Turabian Style

Ricci, Federico, Francesco Bandello, Pierluigi Navarra, Giovanni Staurenghi, Michael Stumpp, and Marco Zarbin. 2020. "Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches" International Journal of Molecular Sciences 21, no. 21: 8242. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21218242

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop